FDA-cleared profile

CINA

AVICENNA.AI

CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified radiologists and other trained imaging professionals.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Radiology workstations, connected imaging environments, or other exact-release CT-processing workflows.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
CT image networking, processing, enhancement, triage, measurement, or professional workflow support.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Processed CT image objects, measurements, notifications, or worklist outputs for professional review.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. CINA analyzes nonenhanced head CT for suspected intracranial hemorrhage and head CTA for suspected large-vessel occlusion for computer-aided triage and notification in parallel with standard care; the output is not a primary diagnosis.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K200855
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Brain
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2020-06-24
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Public source Exact FDA submission Checked 2026-08-13

Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.

Deployment and data flow
On-premise
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

Workflow role

CT image networking, processing, enhancement, triage, measurement, or professional workflow support.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Processed CT image objects, measurements, notifications, or worklist outputs for professional review.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for K200855 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The exact FDA submission K200855 is the identity anchor. Its public decision material supports the submission-specific product and intended-use summary recorded here; it does not establish a general product-wide sensitivity or specificity value for this dossier.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
93.6%; 97.9%; 87.8%
FDA source Exact FDA submission Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
93.6%; 97.9%; 92.5%
FDA source Exact FDA submission Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K200855

Regulatory verification, validation, and labeling evidence reviewed for exact FDA submission K200855. · The labeled population and test materials for exact submission K200855; a general clinical study population is not established here.

exact submission · Tested version: CINA (K200855) · Sponsor or vendor study

K200855

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

Prenatal Nicotine Exposure Raises Male Blood Pressure via FTO-Mediated NOX2/ROS Signaling.

Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K200855 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

37795601

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Potential antimicrobial cotton fabrics treated with cinnamaldehyde/chitosan-alginate nanocapsules for food packaging purposes.

Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K200855 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

39245090

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Early response of the parathyroid gland to withdrawal of a calcimimetic compound in uremic rats.

Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to K200855 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

31961714

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Central Venous and Abdominal Pressures and the Inferior Vena Cava

Candidate clinical-trial registry record discovered by exact-name or identifier search. · Candidate registry population; product and version linkage to K200855 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

NCT01840670

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

CNS Modification of Food Craving by Neurofeedback

Candidate clinical-trial registry record discovered by exact-name or identifier search. · Candidate registry population; product and version linkage to K200855 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

NCT02480179

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

Reimbursement and coding
Not applicable
Not applicable Not applicable Checked 2026-09-04

CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
20Unreviewed PubMed leads
10Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA identity, indication, modality, anatomy, workflow, and limitations were reviewed using the submission as the identity anchor. Current vendor material is product-family context only. PubMed and ClinicalTrials.gov candidates remain quarantined as product-family evidence because exact submission and version linkage was not established. CMS and openFDA index context was checked. Pricing, security, deployment, reimbursement, contracted services, enabled options, and local interoperability remain unknown unless separately evidenced. Automated exact-name discovery found 20 PubMed and 10 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

FDA product code QAS identifies this device class as Radiological Computer-Assisted Triage And Notification Software. Radiological computer-assisted triage and notification...

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

FDA product code QAS identifies this device class as Radiological Computer-Assisted Triage And Notification Software. Radiological computer-assisted triage and notification...

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16